Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2004-12-15
2008-03-04
Saeed, Kamal A. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S361100
Reexamination Certificate
active
07338972
ABSTRACT:
Substituted 1-alkylamino-1H-indazoles for lowering intraocular pressure and treating glaucoma are disclosed.
REFERENCES:
patent: 4690931 (1987-09-01), Wick et al.
patent: 5011846 (1991-04-01), Gittos et al.
patent: 5151444 (1992-09-01), Ueno et al.
patent: 5290781 (1994-03-01), Espino et al.
patent: 5296504 (1994-03-01), Stjernschantz et al.
patent: 5352708 (1994-10-01), Woodward et al.
patent: 5422368 (1995-06-01), Stjernschantz et al.
patent: 5494928 (1996-02-01), Bös
patent: 5538974 (1996-07-01), Ogawa et al.
patent: 5561150 (1996-10-01), Wichmann
patent: 5571833 (1996-11-01), Kruse et al.
patent: 5578612 (1996-11-01), Macor et al.
patent: 5646173 (1997-07-01), Bös et al.
patent: 5652272 (1997-07-01), Ogawa et al.
patent: 5693654 (1997-12-01), Birch
patent: 5760028 (1998-06-01), Jadhav et al.
patent: 5874477 (1999-02-01), McConnell et al.
patent: 5889052 (1999-03-01), Klimko et al.
patent: 5902815 (1999-05-01), Olney et al.
patent: 6107324 (2000-08-01), Behan et al.
patent: 6660870 (2003-12-01), Ruskinko et al.
patent: 6664286 (2003-12-01), May et al.
patent: 6696476 (2004-02-01), Chen et al.
patent: 6806285 (2004-10-01), May et al.
patent: 6884816 (2005-04-01), May et al.
patent: 7268131 (2007-09-01), Dantanarayana et al.
patent: 2003/0181503 (2003-09-01), May et al.
patent: 0 771 563 (2003-01-01), None
patent: WO 92/00338 (1992-01-01), None
patent: WO 94/03162 (1994-02-01), None
patent: WO 94/13275 (1994-06-01), None
patent: WO 97/35579 (1997-10-01), None
patent: WO 98/18458 (1998-05-01), None
patent: WO 98/31354 (1998-07-01), None
patent: WO 99/59499 (1999-11-01), None
patent: WO 00/12475 (2000-03-01), None
patent: WO 00/12510 (2000-03-01), None
patent: WO 00/35922 (2000-06-01), None
patent: WO 00/44753 (2000-08-01), None
patent: WO 00/77002 (2000-12-01), None
patent: WO 00/77010 (2000-12-01), None
patent: WO 01/40183 (2001-06-01), None
patent: WO 01/70207 (2001-09-01), None
patent: WO 01/70223 (2001-09-01), None
patent: WO 01/70230 (2001-09-01), None
patent: WO 01/70701 (2001-09-01), None
patent: WO 01/70702 (2001-09-01), None
patent: WO 01/70745 (2001-09-01), None
patent: WO 01/85152 (2001-11-01), None
patent: WO 02/40456 (2002-05-01), None
patent: WO 02/098350 (2002-12-01), None
patent: WO 02/098400 (2002-12-01), None
patent: WO 02/098860 (2002-12-01), None
patent: WO 03/000663 (2003-01-01), None
patent: WO 03/051291 (2003-06-01), None
patent: WO 03/051352 (2003-06-01), None
patent: WO 03/053436 (2003-07-01), None
patent: WO 2004/019874 (2004-03-01), None
patent: WO 2004/028451 (2004-04-01), None
patent: WO 2004/054572 (2004-07-01), None
patent: WO 2004/058725 (2004-07-01), None
Antonini et al., “Synthesis, Antitumor Cytotoxicity, and DNA-Binding of NovelN-5,2-Di(α-aminoalkyl)-2,6-dihydropyrazolol[3,4,5-kl]acridine-5-carboxamides,”J. Med. Chem., vol. 44, pp. 3329-3333 (2001).
Antonini et al., 2,6-Di(α-aminoalkyl)-2,5,6,7-tetrahydropyrazolol[3,4,5-mn]pyrimido[5,6,1-de]-acridine-5,7-diones: Novel, Potent, Cytotoxic, and DNA-Binding Agents,J. Med. Chem., vol. 45, pp. 696-702 (2002).
Barben et al., “Heterocyclic Flourine Compounds. Part IV. Monofluoroindazoles,”J. Chem. Soc., p. 672 (1960).
Batt et al., “Disubstituted Indazoles as Potent Antagonists of the Integrin αvβ3,”J. Med. Chem., vol. 43, pp. 41-58 (2000).
Bowen et al., “Nonlinear regression using spreadsheets,”Trends In Pharmacological Sciences, vol. 16, pp. 413-423 (1995).
Chang et al., “Mechanism of the Ocular Hypotensive Action of Ketanserin,”J. of Ocular Pharmacology, vol. 1(2), pp. 137-147 (1985).
Divekar et al. “Reaction of Anhydrosepedonin with Alkali Synthesis of a Degradation Product and Some Related Dimethylhydroxybenzoic Acids,”Canadian J. of Chemistry, vol. 42, pp. 63-68 (1964).
Florella et al., “Role of 5-HT2Aand 5-HT2Creceptors in the stimulus effects of hallucinogenic drugs II: reassessment of LSD false positives,”Psychopharmacology, vol. 121, pp. 357-363 (1995).
Gupta et al., “Therapeutic Potentials of 5-HT Receptor Modulators,”Indian J. of Pharmacology, vol. 26, pp. 94-107 (1994).
Johnson et al., “Binding to the Serotonin 5-Ht2Receptor by the Enantiomers of125I-DO,”Neuropharmacology, vol. 26(12), pp. 1803-1806 (1987).
Krootila et al., “Effect of Serotonin and Its Antagonist (Ketanserin) on Intraocular Pressure in the Rabbit,”J. of Ocular Pharmacology, vol. 3(4), pp. 279-290 (1987).
Mallorga et al., “Characterization of Serotonin Receptors in the Iris + ciliary body of the albino rabbit,”Current Eye Research, vol. 6(3), pp. 527-532 (1987).
Mano et al., “The Effect of Anplag (Sarpogelate HCL), New Selective 5-HT2Antagonist on Intraocular Pressure in Rabbits,”IOVS, vol. 36(4), S719 (1995).
May et al., “A Novel and Selective 5-HT2Receptor Agonist with Ocular Hypotensive Activity: (S)-(+)-1-(2-Aminopropyl)-8,9-dihydropyrano[3,2-e]indole,”J. Med. Chem., vol. 46, pp. 4188-4195 (2003).
May et al., “Evaluation of the Ocular Hypotensive Response of Serotonin 5-HT1Aand 5-HT2Receptor Ligands in Conscious Ocular Hypertensive Cynomolgus Monkeys,”J. of Pharmacology and Experimental Therapeutics, vol. 306(1), pp. 301-309 (2003).
Osborne et al., “Do Beta-Adrenoceptors and Serotonin 5-HT1A Receptors have Similar Functions in the control of Intraocular Pressure in the Rabbit?”,Ophthalmologica, vol. 210, pp. 308-314 (1996).
Osborne et al., “5-Hydroxytryptamine1Aagonists: potential use in glaucoma. Evidence from animal studies,”Eye, vol. 14(38), pp. 454-463 (2000).
Takeda et al., “The Effect of Inplag. Novel Selective 5-HT2Antagonist on Intraocular Pressure in Glaucoma Patients,” IOVS, Vo. 36(4), S734 (1995).
Wang et al., “Effect of 5-methylurapidil, an α1a-adrenergic antagonist and 5-hydroxytryptamine1aagonist, on aqueous humor dynamics in monkeys and rabbits,”Current Eye Research, vol. 16(8), pp. 769-775 (1997).
Wang et al., “Effect ofp-MPPI Hydrochloride (p-MPPI) Applied before 5-methylurapidil (5-MU) on Intraocular Pressure (IOP) In Normal Monkeys,”IOVS, vol. 39(4) (1998).
Dantanarayana Anura P.
May Jesse A.
Alcon Inc.
Ryan Patrick M.
Saeed Kamal A.
LandOfFree
Substituted 1-alkylamino-1H-indazoles for the treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted 1-alkylamino-1H-indazoles for the treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted 1-alkylamino-1H-indazoles for the treatment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3964081